Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Biotech

Celgene

Celgene raises $90B Public at $95B valuation

86 Morris Avenue, Summit, NJ 07901January 1, 20241 min read
Total Raised
$90B
Valuation
$95B
Latest Round
Public
Employees
7000+

Celgene: Public Funding Round

Celgene has successfully raised $90B in Public funding, reaching a valuation of $95B.

Company Overview

Biotechnology company

Funding Details

The Public round was led by Bristol Myers Squibb.

Company Information

  • Headquarters: 86 Morris Avenue, Summit, NJ 07901
  • Founded: 1986
  • Employees: 7000+
  • Category: Biotech

Investment

Celgene plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Bristol Myers Squibb: Verified investor in Public

Company Info

Headquarters
86 Morris Avenue, Summit, NJ 07901
Founded
1986
Team Size
7000+
Last Round
$90B(Jan 2024)

Investors (1)

B
Bristol Myers SquibbLead
Lead Investor
Verified investor in Public

Topics

verified(3079)real-funding(3079)public(927)celgenebiotech86-morris-avenue

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free